Skin Cancer

Atezolizumab, cobimetinib, and vemurafenib in patients with BRAFV600 mutation-positive melanoma with central nervous system metastases: Final results and exploratory biomarker analysis from the phase 2 TRICOTEL study

The phase 2 TRICOTEL study evaluated atezolizumab plus cobimetinib plus vemurafenib in a BRAFV600 wild-type cohort and a BRAFV600 mutation-positive melanoma with CNS metastases cohort. This poster presents the final analysis results and exploratory biomarker analyses for patients with BRAFV600-mutated melanoma treated with the triplet therapy combination.

Independent content

European Society for Medical Oncology ESMO 2022 Annual Meeting: Melanoma

The Annual Meeting of the European Society of Medical Oncology (ESMO) was a hybrid meeting, with delegates attending in person for the first time since before the pandemic.

Time to Development of Central Nervous System Metastases With Atezolizumab or Placebo Combined With Vemurafenib + Cobimetinib: Updated Results From the Phase 3 IMspire150 Study

The phase 3 IMspire150 study demonstrated improved progression-free survival with first-line combination treatment with the combination of atezolizumab, vemurafenib, and cobimetinib compared with placebo, vemurafenib, and cobimetinib in patients with previously untreated BRAFV600 mutation–positive advanced melanoma. This poster describes results of an exploratory analysis to evaluate incidence and time to development of CNS metastases in the IMspire150 study.

A Phase 1b/2 Multicenter, Randomized, Umbrella Study Evaluating Novel Treatment Combinations in Melanoma (MORPHEUS-MELANOMA)

This poster describes the design of a phase 1b/2 multicenter, randomized, open-label, umbrella study (MORPHEUS-MELANOMA) to evaluate the safety, efficacy, and pharmacokinetics of various novel treatments or treatment combinations targeting multiple immune evasion mechanisms in patients with treatment-naive, resectable stage III melanoma and in patients with previously treated stage IV melanoma.

Overall Survival (OS) With First-Line Atezolizumab or Placebo in Combination With Veruraenib and Cobimetinib in BRAFV600 Mutation-Positive Advanced Melanoma: Second Interim OS Analysis of the Phase 3 IMspire150 Study

Primary analysis of the phase 3 IMspire150 study (NCT02908672) demonstrated improved investigator-assessed progression-free survival (PFS) with first-line atezolizumab + vemurafenib + cobimetinib (A + V + C) versus placebo + vemurafenib + cobimetinib (P + V + C) in patients with previously untreated BRAFV600 mutation–positive advanced melanoma (hazard ratio [HR] 0.78; 95% CI, 0.63-0.97; P=0.025)1.

Systematic Literature Review and Network Meta-Analysis of Immunotherapy, Targeted Agents or Combination Regimens in Treatment-Naïve Unresectable or Metastatic Melanoma

This systematic literature review and network meta-analysis compared the safety and efficacy of atezolizumab plus cobimetinib plus vemurafenib (ACV) to other therapies for treatment-naive adults with unresectable or metastatic melanoma and found that ACV had the highest PFS benefit and a low rate of treatment discontinuation compared to other therapies.

External site

Skin Cancer

Ask a question or share feedback